LL-37 Dosage, Reconstitution & Mixing Trends

Explore ll-37 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized ll-37 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What LL-37 Is

LL-37 is a 37-residue human cathelicidin peptide — the body's only cathelicidin — most often sourced for antimicrobial, wound-healing, and immune research. It works as both a broad-spectrum antimicrobial and an immune-signaling molecule. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]

LL-37 is amphipathic and α-helical; it inserts into negatively charged bacterial membranes (which expose anionic phospholipids and lipopolysaccharide that mammalian membranes do not) and disrupts membrane integrity, killing a wide range of Gram-positive, Gram-negative, fungal, and enveloped-viral pathogens.[1][2] Beyond direct microbial killing, LL-37 binds the formyl-peptide receptor 2 (FPR2/ALX) on neutrophils, monocytes, and endothelial cells to drive chemotaxis, modulate cytokine release, and accelerate wound healing — the basis for its established role in cutaneous host defence and wound repair.[2][3]

Topical and parenteral LL-37 has been investigated in chronic wound healing, venous leg ulcers (Gronberg et al., Phase 2 randomised trial reported accelerated healing), inflammatory skin conditions, and adjunct antimicrobial therapy for antibiotic-resistant infections.[3][4] LL-37 has also been studied as a biomarker in vitamin-D-dependent host defence and in the pathophysiology of psoriasis and rosacea where it can drive autoinflammation.[5] No FDA-approved LL-37 drug product exists, though it is in active early-stage clinical development.[6]

Not FDA-approved. Phase 1–2 clinical work in wound healing and topical infection (notably the Gronberg ulcer trials). Research-grade material for non-clinical use; no chronic systemic-use human safety data exists.

LL-37 Research Sources

LL-37 Dosing Context

LL-37 has a reported half-life of ~30–60 min. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. Short half-life — this cathelicidin peptide clears within about an hour, so daily dosing acts per-dose with no meaningful systemic accumulation. Pharmacokinetic source: Pre-clinical cathelicidin (LL-37) pharmacokinetic studies. It is catalogued under Skin Peptides on WPA.

LL-37 Community Calculator Data

98 LL-37 reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

LL-37 Research Background and Calculator Data

LL-37 is the only known human cathelicidin antimicrobial peptide — a 37-amino-acid amphipathic α-helical peptide cleaved from the C-terminus of the precursor protein hCAP-18, encoded by the CAMP gene and stored in the secondary granules of neutrophils, with additional expression in keratinocytes, epithelial cells of the airway and gut, and mast cells. It was first characterized in the mid-1990s through the work of Birgitta Agerberth, Hans Boman, Margherita Zanetti, and Richard Gallo, and the downstream literature established it as a multifunctional component of innate immunity: it kills a broad spectrum of bacteria, fungi, and enveloped viruses through membrane permeabilization; modulates dendritic cell maturation and chemotaxis; promotes angiogenesis and re-epithelialization in wound models; and disrupts bacterial biofilms at concentrations below those required for direct bactericidal action. The clinical record on LL-37 itself is unusually thin given the depth of the preclinical work — the Lytix Biopharma "OP-145" program (a synthetic LL-37-derived antimicrobial) advanced through Phase II evaluation in chronic suppurative otitis media, and several topical LL-37 formulations have been studied in venous leg ulcers and chronic wounds, but no LL-37 product holds an FDA-approved labeled indication, and there is no published controlled human study of subcutaneous injectable LL-37 at any dose.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.